Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma.

about

Rho GDP dissociation inhibitor-β in renal cell carcinoma.A CARP-1 functional mimetic loaded vitamin E-TPGS micellar nano-formulation for inhibition of renal cell carcinoma.

P2860

Q47096248-573C317E-0364-4F2F-BA48-FD7A930CEA1E Q47132952-706C1E17-FD27-4C05-BB46-477ED44B3C8D

P2860

Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma.

Item

http://www.wikidata.org/entity/Q38868038

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma.

@en

type

Item

label

Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma.

@en

prefLabel

Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma.

@en

P1476

Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma.

@en

P2093

Axel S Merseburger

http://www.w3.org/2001/XMLSchema#string

C A VON Klot

http://www.w3.org/2001/XMLSchema#string

Markus A Kuczyk

http://www.w3.org/2001/XMLSchema#string

P2860

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

P304

903-908

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MCO.2016.856

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27313856

http://www.w3.org/2001/XMLSchema#string

P932

4888023

http://www.w3.org/2001/XMLSchema#string

Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma.

about

P2860

P2860

Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932